Articles with public access mandates - Matthieu Schapira - Wellcome TrustLearn more
NoteFor this mandate, articles should be available from specific locations.
Not available based on mandate: 33
Targeted protein degradation: expanding the toolbox
M Schapira, MF Calabrese, AN Bullock, CM Crews
Nature reviews Drug discovery 18 (12), 949-963, 2019
Protein arginine methylation: from enigmatic functions to therapeutic targeting
Q Wu, M Schapira, CH Arrowsmith, D Barsyte-Lovejoy
Nature reviews Drug discovery 20 (7), 509-530, 2021
BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence
L Gu, SC Frommel, CC Oakes, R Simon, K Grupp, CY Gerig, D Bär, ...
Nature genetics 47 (1), 22-30, 2015
Structure-based optimization of a small molecule antagonist of the interaction between WD repeat-containing protein 5 (WDR5) and mixed-lineage leukemia 1 (MLL1)
M Getlik, D Smil, C Zepeda-Velazquez, Y Bolshan, G Poda, H Wu, A Dong, ...
Journal of medicinal chemistry 59 (6), 2478-2496, 2016
Structural chemistry of human RNA methyltransferases
M Schapira
ACS chemical biology 11 (3), 575-582, 2016
Crystal structures of the human histone H4K20 methyltransferases SUV420H1 and SUV420H2
H Wu, A Siarheyeva, H Zeng, R Lam, A Dong, XH Wu, Y Li, M Schapira, ...
FEBS letters 587 (23), 3859-3868, 2013
Identification and structure–activity relationship of HDAC6 zinc-finger ubiquitin binding domain inhibitors
R Ferreira de Freitas, RJ Harding, I Franzoni, M Ravichandran, MK Mann, ...
Journal of Medicinal Chemistry 61 (10), 4517-4527, 2018
Discovery of a potent and selective coactivator associated arginine methyltransferase 1 (CARM1) inhibitor by virtual screening
R Ferreira de Freitas, MS Eram, D Smil, MM Szewczyk, S Kennedy, ...
Journal of medicinal chemistry 59 (14), 6838-6847, 2016
Kinetic characterization of human histone H3 lysine 36 methyltransferases, ASH1L and SETD2
MS Eram, E Kuznetsova, F Li, E Lima-Fernandes, S Kennedy, I Chau, ...
Biochimica et Biophysica Acta (BBA)-General Subjects 1850 (9), 1842-1848, 2015
A basic post-SET extension of NSDs is essential for nucleosome binding in vitro
A Allali-Hassani, E Kuznetsova, T Hajian, H Wu, L Dombrovski, Y Li, ...
Journal of biomolecular screening 19 (6), 928-935, 2014
Chemical inhibition of protein methyltransferases
M Schapira
Cell chemical biology 23 (9), 1067-1076, 2016
Discovery of a potent class I protein arginine methyltransferase fragment inhibitor
R Ferreira de Freitas, MS Eram, MM Szewczyk, H Steuber, D Smil, H Wu, ...
Journal of medicinal chemistry 59 (3), 1176-1183, 2016
Probing the epigenome
A Huston, CH Arrowsmith, S Knapp, M Schapira
Nature Chemical Biology 11 (8), 542-545, 2015
Disease association and druggability of WD40 repeat proteins
R Song, ZD Wang, M Schapira
Journal of proteome research 16 (10), 3766-3773, 2017
Small molecule antagonists of the interaction between the histone deacetylase 6 zinc-finger domain and ubiquitin
RJ Harding, R Ferreira de Freitas, P Collins, I Franzoni, M Ravichandran, ...
Journal of Medicinal Chemistry 60 (21), 9090-9096, 2017
Methyltransferase inhibitors for modulation of the epigenome and beyond
M Schapira, CH Arrowsmith
Current Opinion in Chemical Biology 33, 81-87, 2016
New small molecule inhibitors of histone methyl transferase DOT1L with a nitrile as a non-traditional replacement for heavy halogen atoms
SS Spurr, ED Bayle, W Yu, F Li, W Tempel, M Vedadi, M Schapira, ...
Bioorganic & Medicinal Chemistry Letters 26 (18), 4518-4522, 2016
The promise and peril of chemical probe negative controls
J Lee, M Schapira
ACS chemical biology 16 (4), 579-585, 2021
Genetic variability of the SARS-CoV-2 pocketome
S Yazdani, N De Maio, Y Ding, V Shahani, N Goldman, M Schapira
Journal of Proteome Research 20 (8), 4212-4215, 2021
Structure-based view of the druggable genome
J Wang, S Yazdani, A Han, M Schapira
Drug Discovery Today 25 (3), 561-567, 2020
Publication and funding information is determined automatically by a computer program